The pursuit of new therapies is often a study in calculated risk, where the final stages of clinical testing serve as the ultimate arbiter of a drug’s viability. Novartis recently encountered this reality, announcing the discontinuation of two late-stage programs aimed at treating cancer-related blood clots. The decision followed clinical trial data that revealed "inferior efficacy," a clinical euphemism for a candidate that simply could not outperform or match the current standard of care.
The programs focused on venous thromboembolism, a frequent and dangerous complication for oncology patients. Managing blood clots in this population is a delicate pharmaceutical balancing act: the treatment must be potent enough to prevent life-threatening blockages but refined enough to avoid triggering internal bleeding. The drug candidate in question had been part of Novartis's portfolio since 2019, representing a significant investment in the company’s mid-to-late-stage pipeline.
This retreat highlights the persistent "valley of death" in drug development, where even well-funded candidates can fail just as they approach the regulatory finish line. For Novartis, the move signals a further sharpening of its research focus. As the company leans more heavily into high-growth frontiers like radioligand therapies and RNA-based medicines, it is increasingly willing to prune established programs that fail to meet the high bar of clinical superiority.
With reporting from Endpoints News.
Source · Endpoints News
